vimarsana.com

Page 15 - நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் தி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Engine No 1 Formally Nominates Four Director Candidates to ExxonMobil Board

Engine No. 1 Formally Nominates Four Director Candidates to ExxonMobil Board Engine No. 1 Formally Nominates Four Director Candidates to ExxonMobil Board Engine No. 1, a new investment firm that seeks to enhance long-term value through active ownership, today announced that it has formally nominated four highly qualified, independent director candidates with diverse track records of success across the energy sector to the Exxon Mobil Corporation (NYSE: XOM) (ExxonMobil or the Company) Board of Directors (the Board) in connection with the 2021 Annual Meeting of Shareholders. More information about this campaign can be found at Engine No. 1 stated: Investors increasingly want to see companies focused on the long-term and ExxonMobil is no exception. We believe that ExxonMobils Board needs new members who have proven success positioning energy companies for today as well as tomorrow, and who are sufficiently independent from the current Board to ensure a clean break from a strat

Land & Buildings Issues Letter to Monmouth Real Estate Shareholders

Press release content from Business Wire. The AP news staff was not involved in its creation. Land & Buildings Issues Letter to Monmouth Real Estate Shareholders January 26, 2021 GMT STAMFORD, Conn. (BUSINESS WIRE) Jan 26, 2021 Land & Buildings Investment Management, LLC (together with its affiliates, “Land & Buildings”) today issued the following letter to shareholders of Monmouth Real Estate Investment Corporation (NYSE: MNR) (“Monmouth” or the “Company”) regarding the Company’s flawed strategic alternatives process and Land & Buildings’ nomination of four highly-qualified director candidates for election at Monmouth’s 2021 Annual Meeting of Shareholders (“2021 Annual Meeting”). The full text of the letter follows: January 26, 2021

Archrock Announces Changes to Board of Directors

Archrock Announces Changes to Board of Directors /EIN News/ HOUSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) Archrock, Inc. (NYSE:AROC) (“Archrock” or the “Company”) today announced that, on January 20, 2021, Wendell R. Brooks notified the Company of his retirement from the Company’s Board of Directors (the “Board”).  Mr. Brooks has served on the Board since 2015, including as a member of the audit and compensation committees. On January 20, 2021, the Board appointed Leonard W. Mallett to fill the vacant Board seat resulting from Mr. Brooks’s retirement, effective immediately.  Mr. Mallett will serve as a member of the compensation committee of the Board.

Starboard Delivers Letter To Corteva Board Chair

Starboard Delivers Letter To Corteva Board Chair Reiterates its Belief that Corteva s Operating Performance Dramatically Understates the Intrinsic Value of its Assets Questions the Board s Reluctance to Seriously Consider Leadership Change in Light of Missed Promises and Unforced Errors Under Current CEO Jim Collins Has Nominated a Slate of Eight Highly-Qualified Director Candidates for Election at the Company s 2021 Annual Meeting News provided by Share this article Share this article NEW YORK, Jan. 21, 2021 /PRNewswire/  Starboard Value LP (together with its affiliates, Starboard ), one of the largest shareholders of Corteva, Inc. (NYSE: CTVA) ( Corteva or the Company ), today announced that it has delivered a letter to Gregory Page, Chairman of the Company s Board of Directors (the Board ).

GT Biopharma Appoints Two New Independent Directors

GT Biopharma Appoints Two New Independent Directors News provided by Share this article Share this article BEVERLY HILLS, Calif., Jan. 19, 2021 /PRNewswire/ GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company s proprietary NK cell engager (TriKE™) technology platform today announced the appointment of Michael Breen and Rajesh Shrotriya MD to the Company s Board of Directors (the Board ), effective immediately. Mr. Breen and Dr. Shrotriya bring strong operational skills, deep understanding of drug development and significant leadership experience to the Board. We are pleased to welcome Michael and Rajesh to the GT Biopharma Board, said Anthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma. As part of our transition to NASDAQ we have now reconstituted our board. Michael and Rajesh bring unique skills and expertise, as well as significant experience serving on boards of directors of

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.